Universal screening for chronic hepatitis C virus

Liver International

Volumn 36, Issue , 2016, Pages 62-66

  Shiffman, Mitchell L ^a  

^a Bon Secours Health System   (United States)

Author keywords

Hepatitis C virus; Risk factors; Sustained virological response; Universal screening

Indexed keywords

ANTIVIRUS AGENT; NARCOTIC AGENT; HEPATITIS C ANTIBODY;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; COMORBIDITY; DISEASE COURSE; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; SCREENING; BLOOD; GLOBAL HEALTH; HEALTH CARE DELIVERY; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MASS SCREENING; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; GLOBAL HEALTH; HEALTH SERVICES ACCESSIBILITY; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MASS SCREENING;

EID: 84952837127     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13012     Document Type: Review

References (35)

1. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160: 293-300.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
3. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887-91.
4. El-Serg HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 87-106.
5. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-82.
6. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29: 1596-601.
7. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36: S93-8.
8. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21.
9. Zalesak M, Francis K, Gedeon A, et al. Current and future disease progression of the chronic HCV population in the United States. PLoS ONE 2013; 8: e63959.
10. Ward JW. The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States. Clin Liver Dis 2013; 17: 1-11.
11. Smith BD, Morgan RL, Beckett GA, et al. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012; 157: 817-22.
12. Denniston MM, Klevins RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology 2012; 55: 1652-61.
13. Moyer VA. Screening for hepatitis C infection in adults. US preventative services task force recommendation statement. Ann Intern Med 2013; 159: 349-57.
14. Hsu L, Bowlus CL, Stewart SL, et al. Electronic messages increase hepatitis B screening in at-risk Asian American patients: a randomized, controlled trial. Dig Dis Sci 2013; 58: 807-14.
15. Gailbraith JW, Franco RA, Donnelly JP, et al. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology 2015; 61: 776-82.
16. Turner BJ, Taylor BS, Hanson JT, et al. Implementing hospital-based baby boomer C virus screening and linkage to care: strategies, results and costs. J Hosp Med 2015; 10: 510-6.
17. Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Birth cohort screening for chronic hepatitis during colonoscopy appointments. Am J Gastroenterol 2013; 108: 981-9.
18. Myers RP, Crotty P, Town S, et al. Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study. CMAJ Open 2015; 3: E62-7.
19. Mahajan R, Xing J, Liu SJ, et al. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis 2014; 58: 1055-61.
20. Liu Y, Lawrence RH, Falck-Ytter Y, Watts B, Hirsch AA. Evaluating a hepatitis c quality gap: missed opportunities for HCV-related cares. Am J Manag Care 2014; 20: e257-64.
21. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med 2013; 368: 1859-61.
22. Sulkowski MS, Cooper C, Hunyady B, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011; 8: 212-23.
23. Trooskin SB, Poceta J, Towey CM, et al. Results from a geographically focused, community-based HCV screening, linkage-to-care and patient navigation program. J Gen Intern Med 2015; 30: 950-7.
24. Shiffman ML, Benhamou Y. Cure of HCV related liver disease. Liver Int 2015; 35(Suppl. 1): 71-7.
25. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
26. Harris DR, Gonin R, Alter HJ, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001; 134: 120-4.
27. Westin J, Lagging LM, Spak F, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat 2002; 9: 235-41.
28. Cheung O, Sterling RK, Salvatori J, et al. Mild alcohol consumption is not associated with increased fibrosis in patients with chronic hepatitis C. J Clin Gastroenterol 2011; 45: 76-82.
29. Shiffman ML, Sterling RK, Contos M, et al. Long term changes in liver histology following treatment of chronic hepatitis C virus. Ann Hepatol 2014; 13: 340-9.
30. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97: 2408-14.
31. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 1979-91.
32. Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 27-33.
33. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36(Suppl. 1): S65-73.
34. Valerio H, Goldberg DJ, Lewsey J, et al. Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: implications for reinfection. Drug Alcohol Depend 2015; 154: 125-31.
35. Marco A, Esteban JI, Solé C, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol 2013; 59: 45-51.